๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II Trial of Syncopated Thalidomide, Lenalidomide, and Weekly Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

โœ Scribed by Madiha Tufail; David S. Siegel; Laura McBride; Elizabeth Bilotti; Erica Bello; Palka Anand; Karly Olivo; Urszula Bendarz; Ann McNeill; David H. Vesole

Book ID
119219024
Publisher
Elsevier
Year
2012
Tongue
English
Weight
235 KB
Volume
12
Category
Article
ISSN
2152-2650

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II clinical trial of arsenic triox
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma
โœ C.C. Hofmeister; B. Jansak; N. Denlinger; E.H. Kraut; D.M. Benson; S.S. Farag ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 90 KB

In patients with multiple myeloma, there is preclinical justification to combine arsenic trioxide (ATO and As 2 O 3 ) with DVd (Doxil TM , vincristine, and dexamethasone) for newly diagnosed patients. Eleven patients on this phase II trial received 0.15 mg/kg of ATO for five consecutive days followe

A Phase II trial of pegylated liposomal
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
โœ Mohamad A. Hussein; Laura Wood; Eric Hsi; Gordan Srkalovic; MaryAnn Karam; Paul ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 91 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Patients with multiple myeloma (MM) have increased bone marrow angiogenesis, a low plasma cell labeling index, and multidrug resistance (the primary cause of chemotherapy failure). MM patients receiving the vincristine, doxorubicin, and dexamethasone (VAD) regimen develop